Recent advances in the treatment of visceral leishmaniasis.
Davidson
R N
RN
St Mary's Hospital Medical School Department of Infectious and Tropical Diseases, Lister Unit, Harrow, Middlesex, UK.
Croft
S L
SL
D000666:Amphotericin B / Q000627:therapeutic use; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D010303:Paromomycin / Q000627:therapeutic use; D010419:Pentamidine / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D010303:Paromomycin; D010419:Pentamidine; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B; D000967:Antimony Sodium Gluconate